Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI116927

Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a).

M F Linton, R V Farese Jr, G Chiesa, D S Grass, P Chin, R E Hammer, H H Hobbs, and S G Young

Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141-9100.

Find articles by Linton, M. in: PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141-9100.

Find articles by Farese, R. in: PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141-9100.

Find articles by Chiesa, G. in: PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141-9100.

Find articles by Grass, D. in: PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141-9100.

Find articles by Chin, P. in: PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141-9100.

Find articles by Hammer, R. in: PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141-9100.

Find articles by Hobbs, H. in: PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141-9100.

Find articles by Young, S. in: PubMed | Google Scholar

Published December 1, 1993 - More info

Published in Volume 92, Issue 6 on December 1, 1993
J Clin Invest. 1993;92(6):3029–3037. https://doi.org/10.1172/JCI116927.
© 1993 The American Society for Clinical Investigation
Published December 1, 1993 - Version history
View PDF
Abstract

The B apolipoproteins, apo-B48 and apo-B100, are key structural proteins in those classes of lipoproteins considered to be atherogenic [e.g., chylomicron remnants, beta-VLDL, LDL, oxidized LDL, and Lp(a)]. Here we describe the development of transgenic mice expressing high levels of human apo-B48 and apo-B100. A 79.5-kb human genomic DNA fragment containing the entire human apo-B gene was isolated from a P1 bacteriophage library and microinjected into fertilized mouse eggs. 16 transgenic founders expressing human apo-B were generated, and the animals with the highest expression had plasma apo-B100 levels nearly as high as those of normolipidemic humans (approximately 50 mg/dl). The human apo-B100 in transgenic mouse plasma was present largely in lipoproteins of the LDL class as shown by agarose gel electrophoresis, chromatography on a Superose 6 column, and density gradient ultracentrifugation. When the human apo-B transgenic founders were crossed with transgenic mice expressing human apo(a), the offspring that expressed both transgenes had high plasma levels of human Lp(a). Both the human apo-B and Lp(a) transgenic mice will be valuable resources for studying apo-B metabolism and the role of apo-B and Lp(a) in atherosclerosis.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 3029
page 3029
icon of scanned page 3030
page 3030
icon of scanned page 3031
page 3031
icon of scanned page 3032
page 3032
icon of scanned page 3033
page 3033
icon of scanned page 3034
page 3034
icon of scanned page 3035
page 3035
icon of scanned page 3036
page 3036
icon of scanned page 3037
page 3037
Version history
  • Version 1 (December 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts